Obstacles in Utilizing Nanomedicine for Cancer Management

Kamana Singh, Vineeta Kashyap, Addanki P. Kumar

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Nanomedicine and nanotherapeutics have achieved substantial advancements in technology in recent times. Nanoparticles used for targeting cancer cells, tumor microenvironment, and immune system have been extensively modified for a wide range of cancer therapies. Nanomedicine provides more advantages over traditional chemotherapeutic drugs by minimizing systemic cytotoxicity and lack of specificity through targeted treatment, preventing multidrug resistance (MDR), and enhancing the drug capacity and bioavailability. Despite these advantages, not many nanodrugs have been approved for clinical use. However, obstacles like decreased permeability, retention effects, shielding effects, and toxicity restrict the use of nanoparticles and nanomedicine for clinical use. This chapter will highlight the major obstacles faced by the technology toward clinical translation and commercialization.

Original languageEnglish (US)
Title of host publicationNatural Products and Nano-Formulations in Cancer Chemoprevention
PublisherCRC Press
Pages259-274
Number of pages16
ISBN (Electronic)9781000839371
ISBN (Print)9781032313030
DOIs
StatePublished - Jan 1 2023

ASJC Scopus subject areas

  • General Medicine
  • General Biochemistry, Genetics and Molecular Biology
  • General Engineering

Fingerprint

Dive into the research topics of 'Obstacles in Utilizing Nanomedicine for Cancer Management'. Together they form a unique fingerprint.

Cite this